Six-Month Comparison of Coronary Endothelial Dysfunction Associated With Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent

JACC: Cardiovascular Interventions

Volumn 1, Issue 1, 2008, Pages 65-71

  Kim, Jin Won ^a   Suh, Soon Yong ^a   Choi, Cheol Ung ^a   Na, Jin Oh ^a   Kim, Eung Ju ^a   Rha, Seung Woon ^a   Park, Chang Gyu ^a   Seo, Hong Seog ^a   Oh, Dong Joo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; METAL; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL COMPLIANCE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPEATED DRUG DOSE; THROMBOSIS; TREATMENT DURATION; VASOCONSTRICTION; VASODILATATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PACLITAXEL; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL; VASOCONSTRICTION;

EID: 41249089935     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2007.11.002     Document Type: Article

References (22)

1. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
2. Parry T.J., Brosius R., Thyagarajan R., et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 524 (2005) 19-29
3. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
4. Fuke S., Maekawa K., Kawamoto K., et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 71 (2007) 220-225
5. Obata J.E., Kitta Y., Takano H., et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 50 (2007) 1305-1309
6. Guba M., von Breitenbuch, Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
7. Kim J.W., Park C.G., Seo H.S., et al. Delayed severe multivessel spasm and aborted sudden death after Taxus stent implantation. Heart 91 (2005) e15
8. Togni M., Raber L., Cocchia R., et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120 (2007) 212-220
9. Furchgott R.F. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 276 (1996) 1186-1188
10. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315 (1986) 1046-1051
11. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88 (2001) 756-762
12. Carter A.J., Aggarwal M., Kopia G.A., et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63 (2004) 617-624
13. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 24 (2007) 667-678 369
14. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
15. Wheatcroft S., Byrne J., Thomas M., et al. Life-threatening coronary artery spasm following sirolimus-eluting stent deployment. J Am Coll Cardiol 47 (2006) 1911-1912
16. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
17. Kipshidze N., and Leon M.B. Endothelial dysfunction after drug-eluting stent was never predicted in preclinical studies. J Am Coll Cardiol 47 (2006) 1911
18. Hwang C.W., Wu D., and Edelman E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104 (2001) 600-605
19. Serry R., and Penny W.F. Endothelial dysfunction after sirolimus-eluting stent placement. J Am Coll Cardiol 46 (2005) 237-238
20. Gordon J.B., Ganz P., Nabel E.G., et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 83 (1989) 1946-1952
21. Pristipino C., Beltrame J.F., Finocchiaro M.L., et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 101 (2000) 1102-1108
22. Beltrame J.F., Sasayama S., and Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 33 (1999) 1442-1452